# LuTectomy (NCT04430192)

> Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04430192
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Prostatic Neoplasms
- Interventions: 177Lu-PSMA-617
- Enrollment: 20
- Primary outcome: To determine the radiation absorbed dose in the prostate and involved lymph nodes following one or two administrations of Lu-PSMA in men with HRCaP prior to radical prostatectomy

## Commentary we found

- X threads: 23
- YouTube: 9
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=lutectomy-nct04430192

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04430192", "email": "<work email>"}; the inbox owner confirms by the emailed link.